1. use of fibrates other than fenofibrate or fenofibric acid 2. known active infections or other clinical condition that contraindicate pcsk9 inhibitors 3. known systemic hypersensitivity to pcsk9 inhibitors 4. estimated glomerular filtration rate \<30 ml/min/1.73 m2 5. absolute neutrophil count (anc) less than 2000/mm3 6. a platelet count less than 50000/mm3 7. creatine kinase (ck) greater than 3x upper limit of normal (uln) 8. aspartate aminotransferase (ast) or alanine aminotransferase (alt) greater than 3x upper limit of normal (uln) 9. not expected to survive for more than 48 hours from screening 10. unrelated co-morbidity with life expectancy \<3 months. 11. pregnancy 12. any physical examination findings and/or history of any illness that, in the opinion of the study investigator, might confound the results of the study or pose an additional risk to the patient by their participation in the study 13. patient being treated with other immunomodulators (except for glucocorticoids). 14. patient included in any other interventional trial.

1. use of fibrates other than fenofibrate or fenofibric acid 2. known active infections or other clinical condition that contraindicate pcsk9 inhibitors 3. known systemic hypersensitivity to pcsk9 inhibitors 4. estimated glomerular filtration rate \<30 ml/min/1.73 m2 5. absolute neutrophil count (anc) less than 2000/mm3 6. a platelet count less than 50000/mm3 7. creatine kinase (ck) greater than 3x upper limit of normal (uln) 8. aspartate aminotransferase (ast) or alanine aminotransferase (alt) greater than 3x upper limit of normal (uln) 9. not expected to survive for more than 48 hours from screening 10. unrelated co-morbidity with life expectancy \<3 months. 11. pregnancy 12. any physical examination findings and/or history of any illness that, in the opinion of the study investigator, might confound the results of the study or pose an additional risk to the patient by their participation in the study 13. patient being treated with other immunomodulators (except for glucocorticoids). 14. patient included in any other interventional trial.

use of fibrates other than fenofibrate or fenofibric acid known active infections or other clinical condition that contraindicate pcsk9 inhibitors known systemic hypersensitivity to pcsk9 inhibitors estimated glomerular filtration rate <30 ml/min/1.73 m2 absolute neutrophil count (anc) less than 2000/mm3 a platelet count less than 50000/mm3 creatine kinase (ck) greater than 3x upper limit of normal (uln) aspartate aminotransferase (ast) or alanine aminotransferase (alt) greater than 3x upper limit of normal (uln) not expected to survive for more than 48 hours from screening unrelated co-morbidity with life expectancy <3 months. pregnancy any physical examination findings and/or history of any illness that, in the opinion of the study investigator, might confound the results of the study or pose an additional risk to the patient by their participation in the study patient being treated with other immunomodulators (except for glucocorticoids). patient included in any other interventional trial.

use of fibrates other than fenofibrate or fenofibric acid known active infections or other clinical condition that contraindicate pcsk9 inhibitors known systemic hypersensitivity to pcsk9 inhibitors estimated glomerular filtration rate <30 ml/min/1.73 m2 absolute neutrophil count (anc) less than 2000/mm3 a platelet count less than 50000/mm3 creatine kinase (ck) greater than 3x upper limit of normal (uln) aspartate aminotransferase (ast) or alanine aminotransferase (alt) greater than 3x upper limit of normal (uln) not expected to survive for more than 48 hours from screening unrelated co-morbidity with life expectancy <3 months. pregnancy any physical examination findings and/or history of any illness that, in the opinion of the study investigator, might confound the results of the study or pose an additional risk to the patient by their participation in the study patient being treated with other immunomodulators (except for glucocorticoids). patient included in any other interventional trial.

1. use of fibrates other than fenofibrate or fenofibric acid 2. known active infections or other clinical condition that contraindicate pcsk9 inhibitors 3. known systemic hypersensitivity to pcsk9 inhibitors 4. estimated glomerular filtration rate <30 ml/min/1.73 m2 5. absolute neutrophil count (anc) less than 2000/mm3 6. a platelet count less than 50000/mm3 7. creatine kinase (ck) greater than 3x upper limit of normal (uln) 8. aspartate aminotransferase (ast) or alanine aminotransferase (alt) greater than 3x upper limit of normal (uln) 9. not expected to survive for more than 48 hours from screening 10. unrelated co-morbidity with life expectancy <3 months. 11. pregnancy 12. any physical examination findings and/or history of any illness that, in the opinion of the study investigator, might confound the results of the study or pose an additional risk to the patient by their participation in the study 13. patient being treated with other immunomodulators (except for glucocorticoids). 14. patient included in any other interventional trial.

1. use of fibrates other than fenofibrate or fenofibric acid 2. known active infections or other clinical condition that contraindicate pcsk9 inhibitors 3. known systemic hypersensitivity to pcsk9 inhibitors 4. estimated glomerular filtration rate <30 ml/min/1.73 m2 5. absolute neutrophil count (anc) less than 2000/mm3 6. a platelet count less than 50000/mm3 7. creatine kinase (ck) greater than 3x upper limit of normal (uln) 8. aspartate aminotransferase (ast) or alanine aminotransferase (alt) greater than 3x upper limit of normal (uln) 9. not expected to survive for more than 48 hours from screening 10. unrelated co-morbidity with life expectancy <3 months. 11. pregnancy 12. any physical examination findings and/or history of any illness that, in the opinion of the study investigator, might confound the results of the study or pose an additional risk to the patient by their participation in the study 13. patient being treated with other immunomodulators (except for glucocorticoids). 14. patient included in any other interventional trial.